Although PAPP-A is not specific to PE and its levels may also be altered in other gestational complications such as fetal growth restriction, chromosomal abnormalities, or adverse perinatal outcomes, it remains a relevant biomarker of impaired placentation and early trophoblastic dysfunction—core mechanisms in the pathogenesis of PE [25]. Here, PAPPA is linked to fetal growth restriction.